CRISPR Therapeutics Stock News

CRISPR Therapeutics (NASDAQ: CRSP ) stock rose 5% on news the U.K. gave conditional marketing authority to its gene therapy for sickle cell anemia. It's the first authorization in the world for the CR

CRISPR Therapeutics shares have advanced this year, but they're still far from their peak. The company is heading for its biggest moment ever: potential product approval.

One of my favorite investment strategies when seeking forever stocks is to look to past trends that turned stale. Think of some of the hottest sectors in the past five years that saw massive investor

Some of the most exciting opportunities can be found in biotech stocks. In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money.

Growth stocks could lead this latest market rally -- and may deliver growth to your portfolio over time. Amazon and CRISPR Therapeutics are well positioned to benefit from the next bull market.

When it comes to biotech stocks, I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-late stage clinical tr

CRISPR is a leader in the young but promising gene-editing niche. The biotech is getting closer to earning its first major approval.

The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed.

Biotech is still one of the most exciting sectors on the market. Recession-proof, the sector is still thriving with millions of retiring baby boomers, mergers and acquisitions, new innovation, the int

CRISPR Therapeutics could soon have an approved product in its portfolio. The stock's modest valuation suggests there could be significant upside.

There's nothing like a convincing quarterly earnings beat. The gene-editing specialist's net loss was far narrower than expected.

Biotech stocks have been under extreme pressure over the prior 24 months. This industry-wide move lower may have created a handful of once-in-a-lifetime opportunities for investors.

Gene therapy has been on a roller-coaster ride since the first patient was treated 33 years ago. This slow-motion story took another turn this week after a panel of experts potentially set the stage f

Vertex Pharmaceuticals and CRISPR Therapeutics just met with regulators at the Food and Drug Administration. The discussion was about the safety of their gene therapy candidate called exa-cel.

CRISPR Therapeutics AG (CRSP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CRSP crossed above the 20-day moving average, s